Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors
Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors
Biomea Fusion 在 KRAS 突变实体瘤中 BMF-219 的 I/Ib 期临床试验中为首位患者剂量
- BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)
- A pan-KRAS inhibitor targeting multiple KRAS mutations (including G12C, G12D and G12R, among others) has the potential to treat 25-35% of NSCLC patients, 35-45% of CRC patients, and approximately 90% of PDAC patients
- BMF-219 is now in clinical development across eight liquid and solid tumor types, as well as for patients with type 2 diabetes
- BMF-219 是第一个在 KRAS 突变的非小细胞肺癌 (NSCLC)、结直肠癌 (CRC) 和胰腺导管腺癌 (PDAC) 患者中进行临床研究的脑膜素抑制剂
- 靶向多个 KRAS 突变（包括 G12C、G12D 和 G12R 等）的 pan-KRAS 抑制剂有可能治疗 25-35% 的非小细胞肺癌患者、35-45% 的结直肠癌患者和大约 90% 的 PDAC 患者
- BMF-219 目前正在临床开发中，涉及八种液体和实体瘤类型，以及 2 型糖尿病患者
资讯热榜
更新时间